Lexaria Bioscience Corp. LXRP:US | LXX:CSE Drug Delivery Platform Innovator Investor Presentation April 2020 LexariaBioscience.com 1
Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease. 2 2
Lexaria Bioscience – Corporate Highlights • Disruptive, patented technology platform – fast acting, less expensive & more effective oral drug delivery: • Antivirals (COVID-19, infectious diseases); Oral Nicotine; NSAIDs (Ibuprofen, Aspirin); Cannabinoids; Fat-Soluble Vitamins (A,D,E,K); PDE5 Inhibitors (Viagra, Cialis); Hormones (Estrogen, Testosterone) • DehydraTECH ™ : • Patented formulation and dehydration processing method changes how the body detects and absorbs drugs orally • Clinically proven (see: https://www.ncbi.nlm.nih.gov/pubmed/31512143 or https://rdcu.be/bQZZi) • Faster onset/offset and higher bioavailability in capsules, foods, liquids, mixable powders, etc. • 16 patents granted (>60 pending) covering method-of-use , composition-of-matter and medical treatment claims • Programs commenced to prove delivery effectiveness in antiviral therapies for SARS diseases (incl. COVID-19) and other infectious diseases • Oral nicotine products to disrupt the $990 billion global nicotine market • Altria Group international license rights for undisclosed royalty; in discussions with other tobacco/pharma companies Focused on commercialization through partnerships and licensing 3 3
Key Executives, Directors and Advisors Chris Bunka Chairman & CEO Gregg Smith Strategic Advisor • Founder and Private Investor, Evolution VC Partners • Serial entrepreneur involved in several • Early JUUL Labs, Pax Labs, Beyond Meat investor private and public companies since the • Member of Sand Hill Angels – active Silicon Valley angel investment group late 1980’s • Previous Investment Banking roles with Cowen and Company, BOA Merrill Lynch • Extensive experience in the capital markets, corporate governance, M&A Dr. Philip Ainslie Scientific & Medical Advisor and finance • Co-Director for the Centre for Heart, Lung and Vascular Health, Canada • Named inventor on multiple patent • Research Chair in Cerebrovascular Physiology and Professor, School of Health innovations and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia John Docherty, M.Sc. President Brian Quigley Director • Co-Founder of cannabis consulting firm, Green Sky Strategy • Specialist in development of drug • 16 years at Altria Group; with seven of those years spent as president and CEO delivery technologies for U.S. Smokeless Tobacco and Nu-Mark • Former President and COO of Helix BioPharma Corp. (TSX: HBP) • Named inventor on multiple issued and Jamieson Bondarenko, CFA, CMT Capital Markets Advisor pending patents • Capital Markets Advisor to MustGrow Biologics • Pharmacologist and toxicologist • Chairman of BriaCell Therapeutics • Previous Equity Capital Markets roles with Eight Capital, Dundee Securities, HSBC 4
Patented DehydraTECH ™ Drug Delivery Speeds up onset Increases bioavailability Improves drug potency 1 2 3 Combine “API” with Apply to food / carrier Perform dehydration Fatty Acid Oil particles synthesis procedure Fatty Acid API Sorbitol, Gum Arabic, etc. (e.g., LCFA) 4 Render as powder or liquid for use in desired final form factor API = Active Pharmaceutical Ingredient 5 LCFA = Long Chain Fatty Acid (e.g., oleic acid rich sunflower oil) 5
Why Does DehydraTECH Work? Fatty acids are believed to block and shunt bound APIs away from bitter taste receptors* ✓ Close collaboration with largest R&D organization in Canada, the National Research Council, since January 2017 ✓ Thoroughly evaluated through: Lipids enable gastric protection and rapid ✓ Nuclear Magnetic Resonance (NMR); passage** ✓ Fouier Transform Infrared Spectroscopy (FTIR); ✓ Liquid Chromatography-High Resolution Mass Spectroscopy Small intestine quickly absorbs (LC-HRMS); LCFAs into lymphatics ✓ Dynamic Light Scattering (DLS); and Zeta Potential analysis. (bypassing first pass liver effect) and MCFAs via the ✓ NMR molecular characterization has determined liver*** DehyrdraTECH does not create a new molecular entity (NME) for easier path to market ✓ DehydraTECH shown to reduce particle size through a patented, novel method API = Active Pharmaceutical Ingredient LCFA = Long Chain Fatty Acid MCFA – Medium Chain Fatty Acid *Coupland & Hayes (2014). Pharm Res. Nov 31(11); 2921-2939 **Soehngen et al., (1998). Arthritis & Rheumatism. Vol 31, No. 3. 6 ***Iqbal & Hussain (2009). Am J Physiol Endocrinol Metab. Jun;296(6);E1184-94. 6
DehydraTECH – Patented Technology Benefits Masks unwanted Improves speed of Increases Increases brain Reduces Drug taste onset bioavailability absorption Administration Costs Eliminates the Effects are felt within Much more Animal testing Higher ratio of need for sugar- 10-20 min (vs. 60-120 effective at confirms up to drug delivery filled edibles. min). delivering drug 19x improvement lowers overall into bloodstream. drug costs. Patented drug delivery technology improves oral administration of Active Pharmaceutical Ingredients (APIs) 7 7
Lexaria Pharmaceutical Corp. (100% owned) Research or Product Development Underway : Research or Product Development Pending : • Antiviral therapies for SARS diseases (incl. COVID-19) • PDE5 inhibitors (ex. Viagra, Cialis) • Nicotine • Antiviral therapies for infectious diseases • Cannabinoids • Hormones • NSAIDs (Ibuprofen, Aspirin) • Fat-soluble vitamins (A,D,E,K) Higher Bioavailability = Lower dosage Lower Toxicity = Less burden on liver and kidneys 8 8
CORONAVIRUS Disease COVID-19 Status • Currently no available preventative vaccine • Antiviral therapies are being investigated to potentially fight infection • Oral antiviral therapies needed for mass distribution • Many oral antiviral drugs are fat soluble and poorly absorbed, compromising potency and are exceptionally expensive, limiting access if hundreds of millions of doses are required Lexaria’s DehydraTECH – Antiviral Research • DehydraTECH is clinically proven to significantly increase bioavailability for fat soluble drugs • IRB application submitted to study three oral antiviral medications (~20 additional antiviral drug candidates identified) • Pilot human study pending at a leading Canadian university • Objective is to increase potency for greater therapeutic response, tolerability and to lower cost of drugs • Research expected to lead to expanded safety and efficacy testing in coronavirus and other infectious disease animal models Many oral antivirals are poorly absorbed fat soluble drugs which compromises potency and are exceptionally expensive – limiting dosing capability 9 9
Recommend
More recommend
